Evaluation of new FIP immunotherapy for cats being treated with antiviral therapy

Background and purpose of the trial

Feline infectious peritonitis (FIP) has been a challenge for veterinarians and a devastating disease among cats for over half a century and there is currently no legally available treatment option for FIP. This study seeks to determine in a pilot trial whether a new, unapproved immunotherapy compound may be effective in slowing or reversing disease progression in cats with the effusive (wet) form of FIP that are being treated with an antiviral (EIDD-2801) therapy that is currently not approved but available under FDA Emergency Use Authorization for use in people.

The immunotherapy compound has been shown to be effective in eliciting antiviral immune responses and suppression of FIP infection in tests done in the laboratory. The compound has also been administered safely to cats by injection under the skin and orally without inducing significant side effects.

This study will therefore seek to determine if oral administration of the immune stimulant will cause a faster resolution of clinical signs and bloodwork abnormalities and lower rate of FIP relapse post treatment.

Incentives

Drug costs, exam fees, coronavirus PCR, and recheck bloodwork and urinalysis during the 12 weeks of the study.